- You can view the full Pfizer Ratings Report.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 86 points (+0.6%) at 14,846 as of Wednesday, Jun 26, 2013, 11:35 a.m. ET. During this time, 202.4 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 621.9 million. The NYSE advances/declines ratio sits at 2,198 issues advancing vs. 762 declining with 74 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass. Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader index with a two-cent decline to $27.97. Volume for Pfizer currently sits at 24 million shares traded vs. an average daily trading volume of 56.8 million shares. Pfizer has a market cap of $195.79 billion and is part of the health care sector and drugs industry. Shares are up 11.6% year to date as of Tuesday's close. The stock's dividend yield sits at 3.5%. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people worldwide. The company has a P/E ratio of 19.7, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.